REFERENCES 1. Carlisle E, Fischgrund JS. Bone morphogenetic proteins for spinal fusion. Spine J. 2005;5(suppl 5):240S-249S. 2. Ludwig SC, Kowalski JM, Boden SD. Osteoinductive bone graft substitutes. Eur Spine J. 2000;9(suppl 1):S119-S125. 3. Fischgrund JS, Mackay M, Herkowitz HN, et al. 1997 Volvo Award winner in clinical studies. Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine (Phila Pa 1976). 1997;22(24):2807-2812. 4. Bridwell KH, Sedgewick TA, O’Brien MF, et al. The role of fusion and instrumentation in the treatment of degenerative spondylolisthesis with spinal stenosis. J Spinal Disord. 1993;6(6):461-472. 5. Dimar JR, 2nd, Glassman SD, Burkus JK, et al. Two-year fusion and clinical outcomes in 224 patients treated with a single-level instrumented posterolateral fusion with iliac crest bone graft. Spine J. 2009;9(11):880-885. 6. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002;27(16 suppl 1):S26-S31. 7. Ohtori S, Inoue G, Orita S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37(23):E1464-E1468. 8. Bouchard JA, Koka A, Bensusan JS, et al. Effects of irradiation on posterior spinal fusions. A rabbit model. Spine (Phila Pa 1976). 1994;19(16):1836-1841. 9. Hogevold HE, Grogaard B, Reikeras O. Effects of short-term treatment with corticosteroids and indomethacin on bone healing. A mechanical study of osteotomies in rats. Acta Orthop Scand. 1992;63(6):607-611. 10. Burchardt H, Glowczewskie FP, Jr, Enneking WF. The effect of Adriamycin and methotrexate on the repair of segmental cortical autografts in dogs. J Bone Joint Surg Am. 1983;65(1):103-108. 11. Nilsson OS, Bauer HC, Brostrom LA. Methotrexate effects on heterotopic bone in rats. Acta Orthop Scand. 1987;58(1):47-53. 12. Lee TC, Ueng SW, Chen HH, et al. The effect of acute smoking on spinal fusion: an experimental study among rabbits. J Trauma. 2005;59(2):402-408. 13. Brown CW, Orme TJ, Richardson HD. The rate of pseudarthrosis (surgical nonunion) in patients who are smokers and patients who are nonsmokers: a comparison study. Spine (Phila Pa 1976). 1986;11(9):942-943. 14. Zdeblick TA. A prospective, randomized study of lumbar fusion. Preliminary results. Spine (Phila Pa 1976). 1993;18(8):983-991. 15. Boden SD, Sumner DR. Biologic factors affecting spinal fusion and bone regeneration. Spine (Phila Pa 1976). 1995;20(suppl 24):102S-112S. 16. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976). 2006;31(22):2534-2539; discussion 2540. 17. Kerr EJ, 3rd, Jawahar A, Wooten T, et al. The use of osteo-conductive stem-cells allograft in lumbar interbody fusion procedures: an alternative to recombinant human bone morphogenetic protein. J Surg Orthop Adv. 2011;20(3):193-197. 18. Gurr KR, McAfee PC, Warden KE, et al. Roentgenographic and biomechanical analysis of lumbar fusions: a canine model. J Orthop Res. 1989;7(6):838-848. 19. Samartzis D, Shen FH, Matthews DK, et al. Comparison of allograft to autograft in multilevel anterior cervical discectomy and fusion with rigid plate fixation. Spine J. 2003;3(6):451-459. 20. Ohtori S, Suzuki M, Koshi T, et al. Single-level instrumented posterolateral fusion of the lumbar spine with a local bone graft versus an iliac crest bone graft: a prospective, randomized study with a 2-year follow-up. Eur Spine J. 2011;20(4):635-639. 21. Sengupta DK, Truumees E, Patel CK, et al. Outcome of local bone versus autogenous iliac crest bone graft in the instrumented posterolateral fusion of the lumbar spine. Spine (Phila Pa 1976). 2006;31(9):985-991. 22. Kang J, An H, Hilibrand A, et al. Grafton and local bone have comparable outcomes to iliac crest bone in instrumented single-level lumbar fusions. Spine (Phila Pa 1976). 2012;37(12):1083-1091. 23. Grabowski G, Cornett CA. Bone graft and bone graft substitutes in spine surgery: current concepts and controversies. J Am Acad Orthop Surg. 2013;21(1):51-60. 24. Herkowitz HN, Kurz LT. Degenerative lumbar spondylolisthesis with spinal stenosis. A prospective study comparing decompression with decompression and intertransverse process arthrodesis. J Bone Joint Surg Am. 1991;73(6):802-808. 25. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (4 years) pivotal study. Spine (Phila Pa 1976). 2008;33(26):2850-2862. 26. Rihn JA, Kirkpatrick K, Albert TJ. Graft options in posterolateral and posterior interbody lumbar fusion. Spine (Phila Pa 1976). 2010;35(17):1629-1639. 27. Summers BN, Eisenstein SM. Donor site pain from the ilium. A complication of lumbar spine fusion. J Bone Joint Surg Br. 1989;71(4):677-680. 28. Banwart JC, Asher MA, Hassanein RS. Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. Spine (Phila Pa 1976). 1995;20(9):1055-1060. 29. Silber JS, Anderson DG, Daffner SD, et al. Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa 1976). 2003;28(2):134-139. 30. Delawi D, Dhert WJ, Castelein RM, et al. The incidence of donor site pain after bone graft harvesting from the posterior iliac crest may be overestimated: a study on spine fracture patients. Spine (Phila Pa 1976). 2007;32(17):1865-1868. 31. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma. 1989;3(3):192-195. 32. Arrington ED, Smith WJ, Chambers HG, et al. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res. 1996(329):300-309. 33. Bae HW, Zhao L, Kanim LE, et al. Intervariability and intravariability of bone morphogenetic proteins in commercially available demineralized bone matrix products. Spine (Phila Pa 1976). 2006;31(12):1299-1306; discussion 1307-1298. 34. Mroz TE, Joyce MJ, Lieberman IH, et al. The use of allograft bone in spine surgery: is it safe? Spine J. 2009;9(4):303-308. 35. Jamali A, Hilpert A, Debes J, et al. Hydroxyapatitecalcium carbonate (HACC) vs. plaster of Paris: a histomorphometric and radiographic study in a rabbit tibial defect model. Calcif Tissue Int. 2002;71(2):172-178. 36. Carter JD, Swearingen AB, Chaput CD, et al. Clinical and radiographic assessment of transforaminal lumbar interbody fusion using HEALOS collagen-hydroxyapatite sponge with autologous bone marrow aspirate. Spine J. 2009;9(6):434-438. 37. Neen D, Noyes D, Shaw M, et al. Healos and bone marrow aspirate used for lumbar spine fusion: a case controlled study comparing healos with autograft. Spine (Phila Pa 1976). 2006;31(18):E636-E640. 38. Kitchel SH. A preliminary comparative study of radiographic results using mineralized collagen and bone marrow aspirate versus autologous bone in the same patients undergoing posterior lumbar interbody fusion with instrumented posterolateral lumbar fusion. Spine J. 2006;6(4):405-411; discussion 411-402. 39. Vanek P, Bradac O, DeLacy P, et al. Comparison of 3 fusion techniques in the treatment of the degenerative cervical spine disease. Is stand-alone autograft really the “gold standard?”: prospective study with 2-year follow-up. Spine (Phila Pa 1976). 2012;37(19):1645-1651. 40. Walsh WR, Loefler A, Nicklin S, et al. Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic. Eur Spine J. 2004;13(4):359-366. 41. Siebrecht MA, De Rooij PP, Arm DM, et al. Platelet concentrate increases bone ingrowth into porous hydroxyapatite. Orthopedics. 2002;25(2):169-172. 42. Cinotti G, Corsi A, Sacchetti B, et al. Bone ingrowth and vascular supply in experimental spinal fusion with platelet-rich plasma. Spine (Phila Pa 1976). 2012;38(5):385-391. 43. Tsai CH, Hsu HC, Chen YJ, et al. Using the growth factors-enriched platelet glue in spinal fusion and its efficiency. J Spinal Disord Tech. 2009;22(4):246-250. 44. Castro FP, Jr. Role of activated growth factors in lumbar spinal fusions. J Spinal Disord Tech. 2004;17(5):380-384. 45. Acebal-Cortina G, Suarez-Suarez MA, Garcia-Menendez C, et al. Evaluation of autologous platelet concentrate for intertransverse lumbar fusion. Eur Spine J. 2011;20(suppl 3):361-366. 46. Lad SP, Nathan JK, Boakye M. Trends in the use of bone morphogenetic protein as a substitute to autologous iliac crest bone grafting for spinal fusion procedures in the United States. Spine (Phila Pa 1976). 2011;36(4):E274-E281. 47. Urist MR. Bone: formation by autoinduction. Science. 1965;150(3698):893-899. 48. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002;15(5):337-349. 49. Burkus JK, Sandhu HS, Gornet MF. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine (Phila Pa 1976). 2006;31(7):775-781. 50. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976). 2002;27(21):2396-2408. 51. Glassman SD, Carreon L, Djurasovic M, et al. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J. 2007;7(1):44-49. 52. Boden SD, Martin GJ, Jr, Morone M, et al. The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion. Spine (Phila Pa 1976). 1999;24(4):320-327. 53. Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976). 2002;27(23):2662-2673. 54. Haid RW, Jr, Branch CL, Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J. 2004;4(5):527-538; discussion 538-529. 55. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J. 2009;9(8):623-629. 56. Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976). 2008;33(26):2843-2849. 57. Carreon LY, Glassman SD, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion in patients over 60 years of age: a cost-utility study. Spine (Phila Pa 1976). 2009;34(3):238-243. 58. Glassman SD, Dimar JR, 3rd, Burkus K, et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers. Spine (Phila Pa 1976). 2007;32(15):1693-1698. 59. Mummaneni PV, Pan J, Haid RW, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine. 2004;1(1):19-23. 60. Brown A, Stock G, Patel AA, et al. Osteogenic protein-1: a review of its utility in spinal applications. BioDrugs. 2006;20(4):243-251. 61. Cook SD, Dalton JE, Tan EH, et al. In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine (Phila Pa 1976). 1994;19(15):1655-1663. 62. Vaccaro AR, Patel T, Fischgrund J, et al. A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J. 2003;12(5):495-500. 63. Delawi D, Dhert WJ, Rillardon L, et al. A prospective, randomized, controlled, multicenter study of osteogenic protein-1 in instrumented posterolateral fusions: report on safety and feasibility. Spine (Phila Pa 1976). 2010;35(12):1185-1191. 64. Vaidya R. Transforaminal interbody fusion and the “off label” use of recombinant human bone morphogenetic protein-2. Spine J. 2009;9(8):667-669. 65. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19(7):483-486. 66. Vaidya R, Weir R, Sethi A, et al. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence. J Bone Joint Surg Br. 2007;89(3):342-345. 67. Vaidya R, Sethi A, Bartol S, et al. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech. 2008;21(8):557-562. 68. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIFTLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008;8(6):1011-1018. 69. Toth JM, Boden SD, Burkus JK, et al. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976). 2009;34(6):539-550. 70. Vaidya R, Carp J, Sethi A, et al. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2. Eur Spine J. 2007;16(8):1257-1265. 71. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with offlabel usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976). 2006;31(24):2813-2819. 72. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976). 2003;28(12):1219-1224; discussion 1225. 73. Carragee EJ, Mitsunaga KA, Hurwitz EL, et al. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J. 2011;11(6):511516. 74. Lindley EM, McBeth ZL, Henry SE, et al. Retrograde ejaculation after anterior lumbar spine surgery. Spine (Phila Pa 1976). 2012;37(20):1785-1789. 75. Burkus JK, Dryer RF, Peloza JH. Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5 randomized controlled trials: clinical article. J Neurosurg Spine. 2013;18(2):112-121. 76. Lubelski D, Abdullah KG, Nowacki AS, et al. Urological complications following use of recombinant human bone morphogenetic protein-2 in anterior lumbar interbody fusion: presented at the 2012 Joint Spine Section Meeting: clinical article. J Neurosurg Spine. 2013;18(2):126-131. 77. Tepper G, Rabbani R, Yousefzadeh M, et al. quantitative assessment of retrograde ejaculation using semen analysis, comparison to a standardized qualitative questionnaire, and investigating the impact of rhBMP-2. Spine (Phila Pa 1976). 2013;38(10):841-845. 78. Devine JG, Dettori JR, France JC, et al. The use of rhBMP in spine surgery: is there a cancer risk? Evid Based Spine Care J. 2012;3(2):35-41. 79. Mines D, Gu Y, Kou TD, et al. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2011;20(2):111-118. 80. Yang W, Dong Y, Hong Y, et al. Evaluation of anterior vertebral interbody fusion using osteogenic mesenchymal stem cells transplanted in collagen sponge. J Spinal Disord Tech. 2012. 81. Tohmeh AG, Watson B, Tohmeh M, et al. Allograft cellular bone matrix in extreme lateral interbody fusion: preliminary radiographic and clinical outcomes. ScientificWorldJournal. 2012;2012:263637. 82. Ammerman JM, Libricz J, Ammerman MD. The role of Osteocel Plus as a fusion substrate in minimally invasive instrumented transforaminal lumbar interbody fusion. Clin Neurol Neurosurg. 2013;115(7):991-994.